Teva Pharmaceutical TEVA announced that it has entered into a strategic collaboration agreement with China-based Fosun ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with g ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...

Pre-clinical studies of PD-L1-targeted photoimmunotherapy have suggested three complementary mechanisms ... 1) Direct depletion (necrosis) of PD-L1-expressing tumor cells; 2) Activation of anti ...